Stockwell Lynn
Transaction: 02/18/2025
BUY
Change
+30,000
Price
Not reported
Filing
02/18/2025
Type
BUY
Drugs Made In America Acquisition Corp. Ordinary Shares
DMAA • Shell Companies
$10.76
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 43%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$247.48M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Expensive earnings multiple · 36.67Weak liquidity · 0.03Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$10.76
Change0.00%
Shares Out23.00M
Market Cap$247.48M
Enterprise Value$247.57M
52W Range10.17 - 10.64
Beta0.00
P/E37.18
P/B1.05
P/FCF-652.65
EV/EBITDA-94.19
EV/FCF-652.87
Price$10.76
Change0.00%
Shares Out23.00M
Market Cap$247.48M
Enterprise Value$247.57M
52W Range10.17 - 10.64
Beta0.00
P/E37.18
P/B1.05
P/FCF-652.65
EV/EBITDA-94.19
EV/FCF-652.87
Earnings Yield2.69%
FCF Yield-0.15%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio0.03
Quick Ratio0.03
Volume92.42K
Avg Volume113.27K
Investment DNA
How strong this company looks for long-term investors
24
out of 100
Business Quality
Margins, moat, returns
30/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Manageable debt level · 0Expensive earnings multiple · 36.67Weak liquidity · 0.03Weak profitability
Analyst view
No analyst data available now.
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Stockwell Lynn
Transaction: 02/18/2025
BUY
Change
+30,000
Price
Not reported
Filing
02/18/2025
Type
BUY
Drugs Made In America Acquisition LLC
Transaction: 02/18/2025
BUY
Change
+30,000
Price
Not reported
Filing
02/18/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Stockwell Lynn | BUY | +30,000 | Not reported | 02/18/2025 | 02/18/2025 |
| Stockwell Lynn | BUY | +30,000 | Not reported | 02/18/2025 | 02/18/2025 |
| Drugs Made In America Acquisition LLC | BUY | +30,000 | Not reported | 02/18/2025 | 02/18/2025 |
| Drugs Made In America Acquisition LLC | BUY | +30,000 | Not reported | 02/18/2025 | 02/18/2025 |
| Stockwell Lynn | BUY | +400,000 | Not reported | 01/29/2025 | 02/04/2025 |
| Stockwell Lynn | BUY | +400,000 | Not reported | 01/29/2025 | 02/04/2025 |
| Drugs Made In America Acquisition LLC | BUY | +400,000 | Not reported | 01/29/2025 | 02/04/2025 |
| Drugs Made In America Acquisition LLC | SELL | -5,698,363 | $1.50 | 01/29/2025 | 02/04/2025 |
| Worman Glenn C. | BUY | +100,000 | Not reported | 01/29/2025 | 02/03/2025 |
| Do Catherine | BUY | +100,000 | Not reported | 01/29/2025 | 02/03/2025 |
| Prasad Sridhar G. | BUY | +100,000 | Not reported | 01/29/2025 | 02/03/2025 |
| Shulgan Myron W. | BUY | +100,000 | Not reported | 01/29/2025 | 02/03/2025 |
| Worman Glenn C. | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |
| Shulgan Myron W. | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |
| Stockwell Lynn | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |
| Drugs Made In America Acquisition LLC | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |
| Prasad Sridhar G. | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |
| Do Catherine | OTHER | 0 | Not reported | 01/07/2025 | 01/10/2025 |